Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with glivec (imatinib mesylate, gleevec, STI571)

Sarcoma

Volumn 2007, Issue , 2007, Pages

  Pinder, Elizabeth M ^a   Atwal, Gurprit S S ^a   Ayantunde, Abraham A ^a   Khan, Sarah ^a   Sokal, Mike ^a   McCulloch, Tom ^a   Parsons, Simon L ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FUROSEMIDE; IMATINIB;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; ENDOSCOPY; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; GOUT; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MALE; METASTASIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME;

EID: 36949015200     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2007/82012     Document Type: Article

References (14)

1. J. Rosai GIST: an update. International Journal of Surgical Pathology 11 3 2003 177 186
2. F. Duffaud fduffaud@mail.ap-hm.fr J.-Y. Blay Gastrointestinal stromal tumors: biology and treatment. Oncology 65 3 2003 187 197
3. R. P. Dematteo M. C. Heinrich W. M. El-Rifai G. Demetri Clinical management of gastrointestinal stromal tumors: before and after STI-571. Human Pathology 33 5 2002 466 477
4. A. T. van Oosterom allan.vanoosterom@uz.kuleuven.ac.be I. Judson J. Verweij Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet 358 9291 2001 1421 1423
5. H. Joensuu P. J. Roberts M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New England Journal of Medicine 344 14 2001 1052 1056
6. L. Baeksgaard J. B. Sørensen jbsonk@rh.dk Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemotherapy and Pharmacology 51 3 2003 187 192
7. R. P. DeMatteo J. J. Lewis D. Leung S. S. Mudan J. M. Woodruff M. F. Brennan Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of Surgery 231 1 2000 51 58
8. M. H. Shiu G. H. Farr D. N. Papachristou S. I. Hajdu Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 49 1 1982 177 187
9. A. Vora M. Bhutani manishabhutani@hotmail.com A. Sharma V. Raina Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Annals of Oncology 13 11 2002 1833 1834
10. M. S. Cairo mc1310@columbia.edu M. Bishop Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology 127 1 2004 3 11
11. S. Sallan Management of acute tumor lysis syndrome. Seminars in Oncology 28 2001 2, supplement 5 9 12
12. R. V. Smalley A. Guaspari S. Haase-Statz S. A. Anderson D. Cederberg J. A. Hohneker Allopurinol: intravenous use for prevention and treatment of hyperuricaemia. Journal of Clinical Oncology 18 2000 8 1758 1763
13. P. R. Band D. S. Silverberg J. F. Henderson Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. New England Journal of Medicine 283 7 1970 354 357
14. S. C. Goldman J. S. Holcenberg J. Z. Finklestein A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97 10 2001 2998 3003